BUTRANS 20 20 MCG — DIN 02341220
BUPRENORPHINE : 20 MCG · PURDUE PHARMA · PATCH · wholesale supply in Canada
Health Canada status: MARKETED
What is BUTRANS 20?
BUTRANS 20 20 MCG contains BUPRENORPHINE : 20 MCG. It is listed in the Health Canada Drug Product Database under DIN 02341220, held by PURDUE PHARMA, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 26-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BUTRANS 20 used for?
Management of pain severe enough to require daily, continuous, long-term opioid treatment for which alternative options are inadequate. Not for as-needed (prn) use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Buprenorphine cost around the world?
Buprenorphine is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 10 | 65 | AUD███.██ |
| United States | acquisition | 7 | 57 | USD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 15 | 22 | EUR███.██ |
| United Arab Emirates | public | 10 | 10 | AED███.██ |
| South Africa | single exit price | 8 | 10 | ZAR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Saudi Arabia | public | 1 | 7 | SAR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
189 pack listings across 66 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Buprenorphine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Buprenorphine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Buprenorphine, across 15 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PURDUE PHARMA | 11 | 4 | BELBUCA, BUTRANS 10, BUTRANS 15, BUTRANS 20, BUTRANS 5 | Sourceable in Canada |
| BARD PHARMACEUTICALS (1990) INC | 4 | 0 | BAR-BUPRENORPHINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MCG |
|---|---|
| Dosage form | PATCH |
| Route | TRANSDERMAL |
| Pack configuration (monograph) | Available in strengths of 5, 10, 15, and 20 mcg/h. (Specific container details like bottle/blister count not provided in text). |
| Storage | Not explicitly detailed in provided text (standard reference to Part 1 Section 11). Instructions emphasize avoiding direct external heat sources. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Buprenorphine |
|---|---|
| ATC code | N02AE01 |
| AHFS class | 28:08.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02341220 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2341220 |
| Brand name | BUTRANS 20 |
| Generic / active ingredient | BUPRENORPHINE : 20 MCG |
| Market authorization holder | PURDUE PHARMA |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | N02AE01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02AE |
| Current status | MARKETED |
| Status date | 26-May-2010 |
| Original market date | 2010-05-26 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply one patch every 7 days to dry, hairless skin on upper arm, chest, or back. Rotate sites; do not reuse same site for 3 weeks. Titrate slowly, no more than every 3 days. Max dose 20 mcg/h.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to buprenorphine; ileus; suspected surgical abdomen; acute pain; severe respiratory depression; acute asthma; severe CNS depression; MAO inhibitor use; pregnancy/breastfeeding.
Warnings and precautions
Risks of addiction, abuse, misuse; life-threatening respiratory depression; fatal overdose if ingested/chewed; accidental exposure risk (e.g., hugging); interaction with alcohol/benzodiazepines.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 15 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUTRANS 10 | 10 MCG | PATCH | PURDUE PHARMA | MARKETED | 02341212 |
| BUTRANS 15 | 15 MCG | PATCH | PURDUE PHARMA | MARKETED | 02450771 |
| BUTRANS 5 | 5 MCG | PATCH | PURDUE PHARMA | MARKETED | 02341174 |
| BAR-BUPRENORPHINE | 20 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | 02493632 |
| BAR-BUPRENORPHINE | 5 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | 02493608 |
| BAR-BUPRENORPHINE | 10 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | 02493616 |
| BAR-BUPRENORPHINE | 15 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | 02493624 |
| BELBUCA | 600 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED PRE MARKET | 02465272 |
| BELBUCA | 750 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED PRE MARKET | 02465280 |
| BELBUCA | 900 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED PRE MARKET | 02465299 |
2 · Same class — other molecules in ATC N02AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Buprenorphine | BAR-BUPRENORPHINE · BELBUCA · BUTRANS 10 · BUTRANS 15 · BUTRANS 20 · BUTRANS 5 | 15 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02AA | Codein, Combinations With Psycholeptics · Codeine, Combinations Excl. Psycholeptics · Hydromorphone · Morphine · Natural Opium Alkaloids · Opium · Oxycodone · Oxycodone And Naloxone | 378 | 129 |
| N02AX | Tapentadol · Tramadol | 41 | 30 |
| N02AJ | Codeine And Acetylsalicylic Acid · Codeine And Paracetamol · Hydrocodone And Ibuprofen · Oxycodone And Acetylsalicylic Acid · Oxycodone And Paracetamol · Tramadol And Paracetamol | 137 | 21 |
| N02AB | Fentanyl · Pethidine | 105 | 17 |
| N02AF | Butorphanol · Nalbufine | 5 | 2 |
| N02AC | Dextropropoxyphene · Dextropropoxyphene, Comb Excl Psycholept | 7 | 0 |
| N02AD | Pentazocine | 3 | 0 |
| N02AG | Opioids In Comb With Antispasmodics | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BUTRANS 20 called?
The same molecule, Buprenorphine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bupredermal | Latin | Australia |
| Buprenorphine Sandoz | Latin | Australia |
| Norspan | Latin | Australia |
| B-Patch | Latin | Australia |
| Buvidal | Latin | Saudi Arabia |
| Buvidal Monthly | Latin | Australia |
| Buvidal Weekly | Latin | Australia |
| BUTRANS | Latin | Bahrain |
| Subutex | Latin | Australia |
| Sublocade | Latin | Australia |
| TEMGESIC | Latin | Morocco |
| Temgesic Sublingual Tablets | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.